Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1177-1183, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duffy, M. J.
Right arrow Articles by O'Higgins, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duffy, M. J.
Right arrow Articles by O'Higgins, N. J.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1998;44:1177-1183.)
© 1998 American Association for Clinical Chemistry, Inc.

Enzymes and Protein Markers

Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease

Michael J. Duffy1,a, Catherine Duggan1, Hugh E. Mulcahy3, Enda W. McDermott2, and Niall J. O'Higgins2

Departments of
1 Nuclear Medicine and
2 Surgery, St. Vincent's Hospital, Dublin 4, Ireland.
3 Department of Gastroenterology, St. Bartholomew's Hospital, London EC1 M 6BQ, UK.
a Address correspondence to this author at: Department of Nuclear Medicine, St. Vincent's Hospital, Elm Park, Dublin 4, Ireland. Fax 353-1-269 6018; e-mail mjduffy{at}SVHERC.ucd.ie.

Urokinase plasminogen activator (uPA) is a serine protease causally involved in cancer invasion and metastasis. In this study, high concentrations of uPA in primary breast cancers were independently associated with both a shortened disease-free interval and overall survival. For the disease-free interval as endpoint, uPA was a stronger indicator of outcome than lymph node status, whereas for overall survival, nodal status was stronger than uPA. In patients without metastasis to axillary nodes, uPA was also an independent prognostic marker, using both the disease-free interval and overall survival as end points. In contrast to uPA, neither tumor size nor estrogen receptor status was prognostic in the node-negative patients. Measurement of uPA concentrations might thus be of value in selecting the more aggressive subpopulation of node-negative breast cancer patients that could benefit from adjuvant therapy.




The following articles in journals at HighWire Press have cited this article:


Home page
 JNCI J Natl Cancer InstHome page
M. P. Look, W. L. J. van Putten, M. J. Duffy, N. Harbeck, I. J. Christensen, C. Thomssen, R. Kates, F. Spyratos, M. Ferno, S. Eppenberger-Castori, et al.
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients
J Natl Cancer Inst, January 16, 2002; 94(2): 116 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. C. L. Lin, A. S. Eng, N. E. Hen, E. H. L. Ng, and S. H. Chowdhury
Effect of Progesterone on the Invasive Properties and Tumor Growth of Progesterone Receptor-transfected Breast Cancer Cells MDA-MB-231
Clin. Cancer Res., September 1, 2001; 7(9): 2880 - 2886.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. Murr, A. Bergant, M. Widschwendter, K. Heim, H. Schrocksnadel, and D. Fuchs
Neopterin Is an Independent Prognostic Variable in Females with Breast Cancer
Clin. Chem., November 1, 1999; 45(11): 1998 - 2004.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.